🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Here we take a first pass at answering a question that has bugged me for a while - is CH in the blood really reflective of the clonal distribution in the BM? Spoiler alert - NO! Thanks to all involved Blood Cancer Discovery, masterfully lead by Andrew Young aacrjournals.org/bloodcancerdis…

🚨new ASCO guidelines on stage IV NSCLC

Excited to present our work on Telomere biology gene mutations in MDS and IPSS-M(R) work here! Vik Dhillon Jeff Aguilar Karmanos Cancer Institute

Elated to have won the inaugural Michigan Society of Hematology and Oncology (MSHO) - Hematology Jeopardy. Alhamdulillah. Owe a lot to the training at Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute and mentors Abhinav Deol. ASH SAP/book proves to be a faithful companion. #MSHO

Makes the choice of first line therapy trickier. Cost considerations will always keep imatinib alive but may become my first choice over other second generation TKIs.

Thank you very much Ziad Bakouny, MD, MSc & Nazli Dizman for your tremendous help & guidance with our research! IMG Oncologists Toni Choueiri, MD

Excited to present our poster on mutational site-specificity and concordance/discordance characteristics in myeloid sarcoma here at #ASCO24 ! Big thanks to mentor Suresh Balasubramanian cc: Dakshin Padmanabhan Karmanos Cancer Institute IMG Oncologists #leusm

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma. #AJH Mayo Clinic Comprehensive Cancer Center 10 Tables; Algorithms Includes current data including trials published this month! #ASCO24 onlinelibrary.wiley.com/doi/10.1002/aj…

Print version is out! PNH–related thrombosis in the era of novel therapies: a 2043-patient-year analysis. Congrats @carmelogurnari ashpublications.org/blood/article-…

New: cilta-cel, a #CART for multiple myeloma, found highly effective in first real-world study. Read more from Surbhi Sidana, MD and colleagues today in @BloodJournal: ow.ly/PQrC50TEzlh #mmsm #Cartitude

S1826 is a groundbreaking study that deserves major recognition! Huge congratulations to the investigators. After a deep dive into the article and editorial, here are a few personal observations: ⚠️ As a disclaimer, this post is meant to foster a collaborative learning

Exciting updates from Vik Dhillon! latest insights on molecular characteristics of RAS mutations and an innovative ML-based treatment response prediction system. #ASH24 ASH

Happening now! ⁦tariqkewan⁩ delivered a Great talk! #ASH24 ⁦ASH⁩ ⁦Valeria Visconte⁩ ⁦Carmelo Gurnari⁩

Asmita Shukla presenting her findings on clonal evolution in myeloid neoplasms. Stop by poster no: 4254 to learn more #ASH24 ASH Karmanos Cancer Institute Karmanos Hematology/Oncology Fellowship

A great assessment of AI’s potential and limitations in the future. I share similar hopes and aspirations for #AI in medicine. It will likely bring about incredible advancements we can’t yet foresee, but also challenges we haven’t anticipated. Thank you, Vinay Prasad MD MPH!

Congratulations Vik Dhillon Abdulmoiz! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models MDPI Jeff Aguilar Sushmitha Nanja Reddy Julie Boerner Carmelo Gurnari Waled Bahaj, MD tariqkewan Valeria Visconte

Register for the virtual Fundamentals of HCT Training Course to receive a broad intro to #HCT & cellular immunotherapy. This course incorporates case-based learning to emphasize concepts taught, with a strong focus on pharmacotherapeutic management. ow.ly/4fLW50VlXvJ

It’s a nice gesture from @BloodJournal to recognize their reviewers!

The relief I am able to provide my patients is often not the specific tests or the treatments I prescribe. It’s the time spent explaining and reassuring. The human touch is important for healing and peace of mind. No computer can provide that. #MedTwitter

A successful investigator initiated randomized clinical trial is not as easy as it sounds. Many years of work, many barriers to overcome. Time: Idea to Approval: 1-2 years Approval to Opening: 1 year Opening to Accrual: 3-5 years Accrual to Result: 2-5 years Result to